Yes. Raltegravir’s absorption is not significantly affected by food, so the tablet may be taken with or without meals. Consistency in timing helps maintain steady drug levels.
A mild rash may be a common side effect, but if it spreads, is accompanied by fever, or involves swelling of the face or tongue, seek medical attention promptly as this could signal a serious hypersensitivity reaction.
For patients with mild to moderate hepatic impairment, standard dosing is generally considered safe, but liver function tests should be monitored regularly.
Both are integrase inhibitors, but raltegravir (Zepdon) is typically dosed twice daily, whereas dolutegravir is often given once daily. Their resistance profiles and drug-interaction potentials also differ slightly.
Raltegravir is not a controlled substance and is not screened for in standard occupational drug-testing panels.
Yes, but carry the medication in its original labeled container, bring a copy of the prescription, and be aware of any country-specific import restrictions for antiretrovirals.
Certain supplements containing high levels of calcium, magnesium, or aluminium (e.g., antacids, some multivitamins) can reduce raltegravir absorption. Separate dosing by at least 2 hours to minimize this effect.
The expiry date is printed on the package. Store tablets at room temperature and discard them after this date, even if they appear intact.
Yes. Raltegravir is available as a generic tablet of 400 mg, which contains the same active ingredient and therapeutic effect as the branded product.
Most patients achieve a significant reduction in viral load within the first 4 weeks of therapy, with many reaching undetectable levels by 12 weeks when taken as part of an effective combination regimen.
Zepdon contains raltegravir as its active component. Raltegravir belongs to the class of antiretroviral medicines known as integrase strand-transfer inhibitors (INSTIs) and is used to treat human immunodeficiency virus type 1 (HIV-1) infection. Zepdon is supplied as a 400 mg tablet (tab) and is a prescription-only medicine in the United Kingdom, regulated by the Medicines and Healthcare products Regulatory Agency (MHRA). The brand name “Zepdon” is a commercial label; the underlying active ingredient is the same as the generic drug marketed under the name Isentress.
Raltegravir targets a viral enzyme called integrase, which HIV uses to insert its genetic material into the DNA of host immune cells. By binding to the active site of integrase, raltegravir blocks the strand-transfer step of this process, preventing the virus from establishing a permanent infection within the cell.
Because the mechanism is specific to the viral enzyme, raltegravir does not affect human enzymes, which contributes to its generally favourable safety profile.
Zepdon is approved in the United Kingdom for the treatment of HIV-1 infection in adults. It is prescribed as part of a combination antiretroviral therapy (cART) regimen, which typically includes two nucleoside reverse transcriptase inhibitors (NRTIs) alongside an INSTI such as raltegravir.
The drug is not indicated for HIV-2 infection, prophylaxis of HIV exposure, or pediatric use unless a specialist explicitly decides otherwise.
No robust, peer-reviewed evidence supports off-label uses of raltegravir that would meet the criteria for inclusion. Consequently, this section is omitted.
Patients should report persistent or worsening symptoms to a healthcare professional.
This article provides educational information about Zepdon and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
